Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

In the Spotlight

Overcoming Antigen Escape with CAR T-cell Therapy

Hollie J. Jackson and Renier J. Brentjens
Hollie J. Jackson
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renier J. Brentjens
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
2Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York.
3Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: brentjer@mskcc.org
DOI: 10.1158/2159-8290.CD-15-1275 Published December 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Summary: Sotillo and colleagues describe the molecular events associated with apparent loss of target antigen expression following CAR T-cell therapy. We propose that broader immune activation is required to prevent outgrowth of tumor antigen escape variants following targeted therapies. Cancer Discov; 5(12); 1238–40. ©2015 AACR.

See related article by Sotillo et al., p. 1282.

T-cell function can be specifically redirected to a chosen tumor-associated antigen through expression of a chimeric antigen receptor (CAR). CARs consist of an antigen recognition domain, usually a single-chain variable fragment of an immunoglobulin, linked to T-cell activation (CD3ζ) and co-stimulation (commonly CD28 or 4-1BB) intracellular signaling domains. Upon antigen recognition, the T cell becomes activated, proliferates, and secretes cytokines, as well as directly lyses the targeted cell. We, and others, have shown that targeting cancer cells with CD19-specific CARs has immense promise in the context of B-cell acute lymphoblastic leukemia (B-ALL; ref. 1).

CD19 is a marker expressed on B cells as well as most B-cell malignancies; therefore, effective CAR T-cell therapy may result in B-cell aplasias. B-cell aplasia is considered to be an acceptable “on-target off-tumor” toxicity that can be managed clinically with intravenous immunoglobulin infusion. In addition, CD19 is proposed to play a role in B-cell malignancy development and progression, indicating that mutation of CD19 may be detrimental to tumor cell viability and proliferation. However, loss of CD19 and outgrowth of CD19− tumor cells have been reported in both pediatric and adult responders following CD19-targeted CAR T-cell therapy. At the 2014 Annual Society of Hematology meeting, The University of Pennsylvania/Children's Hospital of Pennsylvania reported 10 of 30 pediatric patients relapsed, and 5 of these patients experienced antigen-negative relapse (2). Results from Memorial Sloan Kettering Cancer Center (MSKCC) presented at the 2015 American Society of Clinical Oncology annual meeting demonstrated that 2 of 14 patients experiencing disease relapse had outgrowth of antigen-negative tumor cells (3). The NCI has recently described 2 patients who achieved complete response following CD19-targeted CAR T-cell therapy, but relapsed with CD19-negative disease (4). It is clear from these reports that loss of antigen expression on tumor cells presents a problem that is not specific to any single institute. Antigen loss renders CAR T cells ineffective against B-cell tumors and may have implications for the broader success of CAR T-cell therapies, regardless of the tumor-associated antigen (TAA) targeted.

In this issue, Sotillo and colleagues investigated the molecular events associated with apparent loss of CD19 expression in patients with relapsed disease following CD19-targeted CAR T-cell therapy (5). These studies demonstrated that 1 patient with a CD19 genetic alteration and a second patient without genetic alteration both had increased levels of a CD19 isoform that skipped exon 2 (Δex2). The authors demonstrated that CD19 mRNA can be alternatively spliced, leading to decreased levels of the full-length CD19 isoform and increased levels of the Δex2 isoform. The authors show that the Δex2 isoform of CD19 is more stable than the full-length isoform and can partially rescue functional defects associated with complete loss of expression of CD19 while leading to loss of the cognate CD19 epitope necessary for CART-19 recognition. The authors used cell lines to determine that the splice factor SRSF3 was involved in the inclusion of CD19 exon 2. Subsequently, samples from 2 patients with CD19-negative relapses were shown to have lower amounts of SRSF3 compared with earlier samples. The authors cannot determine whether the mutations identified in these patients select for Δex2 isoform (“permissive” model) or actively redirect the splicing machinery (“instructive” model). It is also plausible that alternative splicing may be epigenetically regulated.

This study, along with evidence of splice variant melanoma cells that are resistant to vemurafenib, is evidence of splice-based adaptations in tumor cells leading to outgrowth of tumor escape variant cells (6). This indicates that future CAR T-cell, monoclonal antibody, or any other targeted therapy may drive the outgrowth of tumor antigen escape variants. Therefore, therapies that recruit a more broadly targeted antitumor immune response will be required if tumor-targeted immunotherapy in general, and CAR T-cell therapy specifically, is going to have universally effective and durable antitumor effects.

One strategy to overcome the outgrowth of antigen loss tumor cells is to equip T cells with two CARs targeted to two different TAAs. Targeting two antigens would mean that escape of CAR T-cell–mediated destruction would require simultaneous mutations in two genes. Preclinical studies have demonstrated that this approach resulted in increased antitumor function compared with a T cell expressing a single CAR (7). Importantly, expression of two CARs in one T-cell population was demonstrated to offset tumor antigen escape. This approach may be a promising strategy for the future CAR T-cell therapy. However, identifying two TAAs on one tumor that can be both safely and effectively targeted with CAR T cells may prove difficult for some malignancies.

Recruitment, restimulation, or rescue of an existing endogenous antitumor immune response may allow for a more broadly targeted antitumor response involving many different effector cell types. Indeed, the endogenous immune system is capable of epitope spreading, which is the generation of an immune response to epitopes distinct from the initial immune-targeted epitope. Immune effector cells associated with tumor cells are often suppressed by the inhibitory immune microenvironment. Inhibitory factors may include ligands for receptors that dampen immune responses (e.g., PD-L1 and/or PD-L2). One approach to modulate the tumor microenvironment is through the addition of checkpoint inhibitors. Immune checkpoint inhibitors prevent ligation of inhibitory receptors (e.g., PD-1 and/or CTLA-4) expressed on T cells, natural killer cells, and other immune effector cells of the immune system. Checkpoint blockade therapy, specifically using monoclonal antibodies that bind and block CTLA-4 or PD-1 T-cell–inhibitory receptors or block the ligands (PD-L1) from interacting, has shown promise in clinical trials. A recent study investigated the molecular determinants of responders and nonresponders to PD-1 antibody and CTLA-4 antibody therapy in patients with non–small cell lung cancer and metastatic melanoma, respectively. Clinical benefit was associated with mutational load and neoantigens in the patient tumor cells (8). It is hypothesized that mutations in tumor cells may generate neoantigens that are presented in the context of HLA molecules. These neoantigens were found to induce specific endogenous T-cell responses that were critical to the overall antitumor efficacy of checkpoint blockade therapy. Therefore, these therapies are thought to rely on the existence of endogenous tumor-specific T cells and the ability of checkpoint inhibitors to overcome the unresponsiveness of these tumor-specific T cells. Indeed, combining CAR T-cell therapy with checkpoint blockade has shown promise in preclinical studies and will be tested in an upcoming clinical trial at Baylor College of Medicine in Texas (NCT00586391). However, this may not be sufficient to prevent outgrowth of tumors that are not recognized by the CAR or endogenous T cells.

Other tactics to improve antitumor efficacy and recruit endogenous immune cells include the development of “armored” CAR T cells that are further modified to secrete immune stimulatory cytokines (e.g., IL12) or express co-stimulatory molecules (e.g., CD40L or 4-1BBL). Further modifying CAR T cells to secrete IL12, a proinflammatory cytokine, resulted in increased antitumor efficacy, as we and others have previously shown (9). Not only does IL12 act in an autocrine fashion and increase the antitumor function of the CAR T cell itself, it is also found to modulate the tumor microenvironment, rendering T cells resistant to suppression from regulatory T cells and myeloid-derived suppressor cells. This approach will be evaluated in the context of solid tumors in patients with ovarian cancer in a trial at MSKCC (NCT02498912). In another strategy, CAR T cells modified to constitutively express CD40L were shown to mature and activate dendritic cells, as well as modulate the tumor phenotype, leading to increased tumor cell immunogenicity (10). Expression of other co-stimulatory ligands, specifically 4-1BBL and CD80, on CAR T cells has also been demonstrated to enhance CAR T-cell function (11). We hypothesize that these immune-stimulatory effects combined will increase the antitumor effect mediated by CAR T cells, as well as recruit an effective endogenous antitumor response (Fig. 1A and B). This may allow for epitope spreading and reduced risk of outgrowth of antigen escape variants.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Immune modulation is required to eradicate tumors in the context of CAR T-cell therapy. A, Sotillo and colleagues (5) describe the molecular mechanisms associated with outgrowth of tumor cells that have mutated the CAR target TAA, resulting in relapse of antigen-negative tumor following CAR T-cell therapy. B, we hypothesize that CAR T-cell therapy with recruitment of endogenous antitumor immune cells will allow epitope spreading and complete eradication of tumor cells even when tumor cells have mutated the CAR target TAA.

In this issue, Sotillo and colleagues demonstrate unique means whereby tumors may mediate immune escape by loss of targeted epitope on an otherwise essential target antigen. These findings are important for developing strategies to overcome the risk of tumor antigen escape in the setting of immune-based antitumor therapies. Further, as CAR T-cell technology moves toward targeting other TAAs, in both the hematologic and solid tumor settings, this report highlights the need to understand the mechanisms whereby tumor cells mediate immune escape in order to optimize immunotherapy of cancer.

Disclosure of Potential Conflicts of Interest

R.J. Brentjens is a scientific co-founder of, reports receiving a commercial research grant from, has ownership interest (including patents) in, and is a consultant/advisory board member for JUNO Therapeutics. No potential conflicts of interest were disclosed by the other author.

  • ©2015 American Association for Cancer Research.

References

  1. 1.↵
    1. Pegram HJ,
    2. Smith EL,
    3. Rafiq S,
    4. Brentjens RJ
    . CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?Immunotherapy 2015;7:545–61.
    OpenUrlPubMed
  2. 2.↵
    1. Grupp SA,
    2. Maude SL,
    3. Shaw P,
    4. Aplenc R,
    5. Barrett DM,
    6. Callahan C,
    7. et al.
    T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) have long term persistence and induce durable remissions in children with relapsed, refractory ALL. Blood 2014;124:380.
    OpenUrl
  3. 3.↵
    1. Park JH,
    2. Riviere I,
    3. Wang X,
    4. Bernal Y,
    5. Purdon T,
    6. Halton E,
    7. et al.
    Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL. J Clin Oncol 33, 2015(suppl; abstr 7010).
  4. 4.↵
    1. Lee DW,
    2. Kochenderfer JN,
    3. Stetler-Stevenson M,
    4. Cui YK,
    5. Delbrook C,
    6. Feldman SA,
    7. et al.
    T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385:517–28.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Sotillo E,
    2. Barrett DM,
    3. Black KL,
    4. Bagashev A,
    5. Oldridge D,
    6. Wu G,
    7. et al.
    Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 2015;5:1282–95.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Poulikakos PI,
    2. Persaud Y,
    3. Janakiraman M,
    4. Kong X,
    5. Ng C,
    6. Moriceau G,
    7. et al.
    RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387–90.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Hegde M,
    2. Corder A,
    3. Chow KK,
    4. Mukherjee M,
    5. Ashoori A,
    6. Kew Y,
    7. et al.
    Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 2013;21:2087–101.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Rizvi NA,
    2. Hellmann MD,
    3. Snyder A,
    4. Kvistborg P,
    5. Makarov V,
    6. Havel JJ,
    7. et al.
    Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124–8.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Pegram HJ,
    2. Lee JC,
    3. Hayman EG,
    4. Imperato GH,
    5. Tedder TF,
    6. Sadelain M,
    7. et al.
    Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012;119:4133–41.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Curran KJ,
    2. Seinstra BA,
    3. Nikhamin Y,
    4. Yeh R,
    5. Usachenko Y,
    6. van Leeuwen DG,
    7. et al.
    Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther 2015;23:769–78.
    OpenUrlPubMed
  11. 11.↵
    1. Stephan MT,
    2. Ponomarev V,
    3. Brentjens RJ,
    4. Chang AH,
    5. Dobrenkov KV,
    6. Heller G,
    7. et al.
    T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 2007;13:1440–9.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Cancer Discovery: 5 (12)
December 2015
Volume 5, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Overcoming Antigen Escape with CAR T-cell Therapy
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Overcoming Antigen Escape with CAR T-cell Therapy
Hollie J. Jackson and Renier J. Brentjens
Cancer Discov December 1 2015 (5) (12) 1238-1240; DOI: 10.1158/2159-8290.CD-15-1275

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Overcoming Antigen Escape with CAR T-cell Therapy
Hollie J. Jackson and Renier J. Brentjens
Cancer Discov December 1 2015 (5) (12) 1238-1240; DOI: 10.1158/2159-8290.CD-15-1275
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Disclosure of Potential Conflicts of Interest
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • At the Heart of Immune Checkpoint Inhibitor–Induced Immune Toxicity
  • Genetic Ancestry Correlations with Driver Mutations Suggest Complex Interactions between Somatic and Germline Variation in Cancer
  • Poorer Clinical Outcomes for Black Patients with AML: A Wake-Up Call for Better Data and Greater Understanding of Cancer Outcomes in All Ethnic Groups
Show more In the Spotlight
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement